Deciphera Pharmaceuticals Quiet Period Ended This Week

Deciphera Pharmaceuticals will likely be pumped by the IPO underwriters soon now that the quiet period has ended.

Deciphera Pharmaceuticals' quiet period ended on Tuesday, November 7, 2017. The brokerages that served as underwriters are working on research reports and will likely release those reports and analyst ratings on this company soon. In other words, the pump of this stock should start any week now. Please review this lesson on institutional traders and market makers.

Progenics Pharmaceuticals 142 Percent Price Target From Cantor Fitzgerald

Cantor Fitzgerald really went out high on Progenics Pharmaceuticals, or did they? Needham and Company also gave this stock its highest Strong Buy rating too.

Progenics Pharmaceuticals had its price target set to $15 by Cantor Fitzgerald. Cantor Fitzgerald has a Buy rating on the stock. Cantor Fitzgerald has struggled over the last year with its performance; however, Needham and Company hasn't.

Verastem Price Target Set 364 Percent Higher By Cantor Fitzgerald

Verastem stock had a price target set 364% higher than its current price by Cantor Fitzgerald. Cantor Fitzgerald has a buy rating on the stock.

Verastem is on track for duvelisib NDA in Q1 2018, to include accelerated approval request for follicular lymphoma. Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.

Sorrento Therapeutics Inc Bounce Off 61.8 Percent Retracement

Sorrento Therapeutics Inc has bounced off its 61.8 percent Fibonacci retracement level.

Verastem Inc Price Target Raised By Cantor Fitzgerald

Verastem Inc price target was raised to $17 by Cantor Fitzgerald last week. The new $17 price target represents 330% upside from the previous close of $3.95. Cantor has a Buy rating on the stock.

Cantor Fitzgerald is respected on Wall Street but they do not have the most accurate analysts IMO. Oppenheimer Holdings Inc is a more followed analyst than Cantor Fitzgerald. It's no surprise then that I think it's more significant that on October 12, 2017, Oppenheimer reiterated their Buy rating on Verastem Inc stock and set a price target of $6 which represents an upside of 52% from the previous close. The $6 price target seems more down-to-earth and achievable than Cantor's stratospheric $17 price target.

Exelixis Gets FDA Priority Review for Cabomteyx

The FDA has granted priority review for Exelixis Cabomteyx. The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma (RCC). The FDA determined the sNDA to be sufficiently complete. This means an FDA approval decision will be made by Feb. 15, 2018.

Sofi AI Market Sentiment Gauge

Sofi AI Market Sentiment Gauge

Market is neither overbought or oversold.